How to Know if Your UDCA Treatment is Working for PBC

To know if your ursodiol (UDCA) treatment for primary biliary cholangitis (PBC) is working, two main things must happen: your daily dose must precisely match your body weight, and your liver blood tests must drop to specific, safe thresholds after one year of treatment ^[1][2].

Because PBC is a chronic disease, you will not usually “feel” if UDCA is working day-to-day. Instead, doctors rely on strict math and standardized blood test criteria to measure success.

Getting the Math Right: Weight-Based Dosing

The absolute foundation of UDCA treatment is weight-based dosing ^[1]. International medical guidelines strictly recommend a dose of 13 to 15 milligrams of UDCA per kilogram of body weight per day (13–15 mg/kg/day) ^[1][3].

Unfortunately, UDCA is frequently under-dosed in clinical practice, which can lead to suboptimal outcomes and allow the disease to progress ^[4][5]. Because the dose is directly tied to your weight, a significant weight gain or loss means your prescription needs to be recalculated by your doctor.

To check your dose at home:

1. Find your weight in kilograms: Divide your weight in pounds by 2.2.
2. Calculate your range: Multiply that number by 13 (for the low end of the range) and 15 (for the high end).
3. Compare to your prescription: Check the total milligrams of all your daily UDCA pills combined (if you take them multiple times a day) to see if the sum falls within that range.

Note: UDCA pills come in set sizes (such as 250 mg, 300 mg, or 500 mg). If your exact mathematical dose is, for example, 940 mg, your doctor will likely round it slightly (like to 1000 mg) to fit the available pill sizes.

The 12-Month Test: Biochemical Response

Doctors do not expect instant results from UDCA. While your doctor will likely order blood tests at 3 and 6 months to monitor early trends and ensure the medication is well-tolerated, the standard medical checkpoint to officially determine if the medication has successfully halted disease progression is at 12 months ^[2][1].

At the one-year mark, your doctor will check your Alkaline Phosphatase (ALP) and total bilirubin levels ^[2][1]. Doctors use standardized scoring systems to decide if the drop in these liver enzymes is considered an “adequate response” (meaning the drug is working well enough to protect your liver).

When reviewing these scores, you will often see the acronym ULN, which stands for the Upper Limit of Normal. Because different laboratories use slightly different machines, the ULN is simply the highest number in the normal reference range printed on your specific lab report.

The two most common scoring systems are:

• The Paris II Criteria: Treatment is considered successful if your ALP is less than or equal to 1.5 times the ULN, your AST (aspartate aminotransferase) is less than or equal to 1.5 times the ULN, and your total bilirubin is normal ^[6]. Meeting this goal is a strong predictor of long-term survival ^[6].
• The Toronto Criteria: Treatment is considered successful if your ALP is less than or equal to 1.67 times the ULN, and your bilirubin remains normal ^[7][8].

Doctors may also use modern risk-calculators, such as the GLOBE score or UK-PBC score ^[9][10]. These plug your blood test results, along with factors like your age and other blood markers, into an algorithm to accurately predict your long-term liver health.

Aiming for a “Deep Response”

While the Paris and Toronto criteria are the traditional benchmarks, newer research suggests an even stricter goal. Achieving a deep response—meaning your ALP and bilirubin return to completely normal levels—provides the best long-term outcomes and the lowest risk of ever needing a liver transplant ^[11][12].

What If UDCA Isn’t Working Enough?

If your blood tests have not dropped to the safe thresholds outlined by the Paris or Toronto criteria after a year, it is known as an “inadequate response” ^[8][13]. This does not mean you did anything wrong, nor does it mean you should stop taking UDCA. Even in patients with an inadequate response, UDCA still provides a survival benefit compared to taking no medication at all.

However, an inadequate response does mean you are at a higher risk for liver-related complications ^[14]. In this scenario, your doctor should prescribe a second-line therapy to take alongside UDCA ^[15]. These add-on medications include obeticholic acid (OCA), fibrates (such as bezafibrate or fenofibrate), or newer approved drugs like elafibranor and seladelpar ^[16][17].